StockMarketWire.com - Silence Therapeutics said it had submitted a clinical trial application to UK authorities for an iron overload disorder treatment.

The treatment, known as SLN124, had been shown to lower serum iron levels, modulate tissue iron distribution and ameliorate anemia in preclinical models.

It represented a highly promising therapeutic candidate medicine for patients with iron overload disorders, the company said.

Subject to approval from the UK Medicines and Healthcare products Regulatory Agency, Silence said the first patient was expected to enter the study in the third quarter of 2019.




Story provided by StockMarketWire.com